全文获取类型
收费全文 | 319篇 |
免费 | 39篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 8篇 |
妇产科学 | 3篇 |
基础医学 | 55篇 |
口腔科学 | 4篇 |
临床医学 | 40篇 |
内科学 | 70篇 |
皮肤病学 | 2篇 |
神经病学 | 9篇 |
特种医学 | 39篇 |
外科学 | 46篇 |
综合类 | 17篇 |
一般理论 | 1篇 |
预防医学 | 35篇 |
眼科学 | 1篇 |
药学 | 17篇 |
肿瘤学 | 18篇 |
出版年
2023年 | 9篇 |
2022年 | 5篇 |
2021年 | 3篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 7篇 |
2017年 | 2篇 |
2016年 | 8篇 |
2015年 | 11篇 |
2014年 | 8篇 |
2013年 | 6篇 |
2012年 | 11篇 |
2011年 | 16篇 |
2010年 | 9篇 |
2009年 | 11篇 |
2008年 | 14篇 |
2007年 | 10篇 |
2006年 | 16篇 |
2005年 | 10篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 5篇 |
2001年 | 9篇 |
2000年 | 3篇 |
1999年 | 6篇 |
1998年 | 15篇 |
1997年 | 3篇 |
1996年 | 8篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 7篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 14篇 |
1987年 | 5篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1982年 | 8篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1969年 | 2篇 |
排序方式: 共有365条查询结果,搜索用时 0 毫秒
361.
362.
Ben A. Croker Joanne A. O'Donnell Cameron J. Nowell Donald Metcalf Grant Dewson Kirsteen J. Campbell Kelly L. Rogers Yifang Hu Gordon K. Smyth Jian-Guo Zhang Michael White Kurt Lackovic Louise H. Cengia Lorraine A. O'Reilly Philippe Bouillet Suzanne Cory Andreas Strasser Andrew W. Roberts 《Proceedings of the National Academy of Sciences of the United States of America》2011,108(32):13135-13140
363.
IL-10 regulation of lupus in the NZM2410 murine model 总被引:3,自引:0,他引:3
Blenman KR Duan B Xu Z Wan S Atkinson MA Flotte TR Croker BP Morel L 《Laboratory investigation; a journal of technical methods and pathology》2006,86(11):1136-1148
Multiple studies have reported high levels of IL-10 in SLE patients and in murine models of lupus. IL-10 is a regulatory cytokine mainly produced by B cells, which use this cytokine to support their proliferation, and by myeloid cells, which use IL-10 to reduce proinflammatory responses. IL-10 is also produced by a subset of CD4+ T regulatory cells. Various manipulations of IL-10 levels with repeated administrations of anti-IL-10 neutralizing antibodies, genetic ablation or injections of recombinant cytokine have shown contradictory results, which is likely to reflect the opposite effects of this cytokine on the two major effector arms of lupus pathologenesis, namely B cells and inflammation. We have investigated the role of IL-10 in a novel congenic model of lupus, B6.Sle1.Sle2.Sle3 (B6.TC), which consists of the three NZM2410-derived SLE susceptibility loci combined on a C57BL/6 background. We first investigated in this model the source of elevated IL-10 and shown that it results from a larger number of CD4+ T cells producing the cytokine, and from a greatly increased B1-a cell pool, which is the main IL-10 producing compartment. We have then used AAV-mediated skeletal muscle gene delivery to overexpress IL-10 in young B6.TC mice and follow disease marker expression up to 7 months of age. We show here that continuous overexpression of low levels of IL-10 significantly delayed antinuclear auto-antibody production and decreased clinical nephritis. B cell phenotypes were largely unaffected, while T-cell activation was significantly reduced. This highlighted the pivotal role played by T-cell activation in this model, and suggested that this pathway could be effectively targeted for therapeutic interventions. These results also reinforce the notion that IL-10 exerts multiple functions and commend caution in equating high levels of IL-10 and increased pathogenesis in systemic autoimmunity. 相似文献
364.
Curtis Croker Roshan Reporter Laurene Mascola 《The American journal of tropical medicine and hygiene》2010,83(1):106-110
Statewide hospital discharge data were used to assess the economic burden of neurocysticercosis in Los Angeles County (LAC) from 1991 through 2008. A neurocysticercosis hospitalization was defined as having a discharge diagnosis of cysticercosis in addition to convulsions, seizures, hydrocephalus, cerebral edema or cerebral cysts. This study identified 3,937 neurocysticercosis hospitalizations, with the number of annual hospitalizations remaining relatively unchanged over the study period (R2 = 0.01), averaging 219 per year (range 180–264). The total of all neurocysticercosis hospitalization charges over the study period was $136.2 million, averaging $7.9 million per year. The average charge per patient was $37.6 thousand and the most common payment method was Medicaid (43.9%), followed by private insurance (24.5%). The average length of stay was 7.2 days. The substantial number of hospitalizations and significant economic cost underscore the importance of neurocysticercosis in LAC. 相似文献